Pharmaceuticals, Biotechnology and Life Sciences
Novartis has updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover.
Vertex Pharmaceuticals Incorporated has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor).
BioMarin Pharmaceuticalsaid today that it got from the European Commission (EC) a grant for Brineura (cerliponase alfa), the first treatment approved in the European Union (EU) for tripeptidyl peptidase 1 (TPP1) deficiency.
Alexion Pharmaceuticals has named several leading chairs to its executive leadership team that will be effective from June 5, 2017.
Rebinyn got US FDA’s approval and is hoped to become an important tool for physicians to help patients manage their bleeds.
The U.S. government may have overpaid drugmaker Mylan N.V. by as much as $1.27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment, the Department of Health and Human Services said on Wednesday.
Drug delivery technology market grows from $1,179.20 billion to $1,669.40 billion at a CAGR of 7.2% from 2016-2021. Oral drug delivery segment is expected to account for the largest share while hospitals segment is expected to account for the largest share of the market and Asia is expected to be fastest-growing region.
Novartis warned on Wednesday that price pressure on its generics drugs in the United States has intensified in the second quarter, cutting into its Sandoz division’s sales growth in the world’s largest healthcare market.
Apotex, Teva Pharmaceuticals USA, Aurobindo Pharma and Glenmark Pharmaceuticals have won FDA’s approval to market atomoxetine in multiple strengths to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.